Braindrp
The biotech licensing portal.
Scroll ↓Pharma's $350B problem*
Biotech deals are complex…
Patent to shelf
Milestone payments for drug deals.
Negotiation
0 –12 months
After R&D and IP diligence, commercial negotiations still take 8 to 12 months to close.
Cost of delay
+$ 0 M per day
Each day a blockbuster patent deal sits in negotiation, pharma loses over $2.7M in revenue.
"… and yet, the IP industry still lacks a shared technology layer."
Instead, work runs on:
Excel the portfolio 
PowerPoint the pitch 
Email the deal 
Outside counsel $1,000+ / email * The $350B problem is the patent revenue cliff for major pharma — branded sales losing exclusivity as patents expire. EY puts US$356 billion of worldwide branded sales at risk from patent expiration between 2023 and 2028. EY, “Navigating pharma loss of exclusivity,” 9 February 2024
How it works
Bloomberg Terminal for Licensing Deals.
Each counterparty 100% authenticated. Standardised licensing and IP formatting across jurisdictions.
Excel portfolio
↓
PowerPoint pitch
↓
Email deal
↓
Dashboard
Patent portfolio management.
Data Room
Securely share assets and market intelligence with any counterparty.
Deal Room
Multi-party negotiations, embedded contracts, and auditable ledgers of milestones.
A deal, captured in milestones
The deal, on Braindrop.
Built for both sides of the deal
Braindrop cuts deal lead-times by over 50% — a win-win for both sides of the market.
Biotech founder
10× the liquidity opportunities, at a fraction of the existing cost (a lifeline).
$30K / year / company
Pharma BD lead
Waste less time on bad deals — get the good ones to market quicker.
$30K / year / seat
Why now
Big pharma's international shopping addiction is about to get worse.
- China now sources ~30% of the global biotech pipeline. †
- Internal R&D no longer fills the gap.
- Clinical trials accelerated by AI.
= more deals to get done
$350bn
Revenue off the patent cliff
2031
So we're building global shopping rails.
† McKinsey puts China alone at 29% of the world’s innovative drug pipeline, with Asia’s share of the global innovative pipeline rising from 28% to 43% in five years. McKinsey, “The emerging epicenter: Asia’s role in biopharma’s future”
Product
The NASDAQ started with ledgers. So do we.
Dashboard
Onboard your whole portfolio in minutes.
Manage
Manage a global estate in classes, not emails and letters.
Data room
Share assets and run auditable due diligence in seconds.
Deal room
License IP, accept offers, and track every milestone.
Built by founding engineers of infrastructure that now facilitate regulated trading volume of hundreds of millions of dollars per day, globally
